Last reviewed · How we verify

Remifentanil and Desflurane — Competitive Intelligence Brief

Remifentanil and Desflurane (Remifentanil and Desflurane) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid agonist and volatile anesthetic combination. Area: Anesthesia.

marketed Opioid agonist and volatile anesthetic combination Mu-opioid receptor (remifentanil); GABA receptors and ion channels (desflurane) Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Remifentanil and Desflurane (Remifentanil and Desflurane) — The Cooper Health System. Remifentanil is an opioid agonist that binds mu receptors to provide analgesia and sedation, while desflurane is a volatile anesthetic that enhances CNS depression through GABA and other ion channel modulation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Remifentanil and Desflurane TARGET Remifentanil and Desflurane The Cooper Health System marketed Opioid agonist and volatile anesthetic combination Mu-opioid receptor (remifentanil); GABA receptors and ion channels (desflurane)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid agonist and volatile anesthetic combination class)

  1. The Cooper Health System · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Remifentanil and Desflurane — Competitive Intelligence Brief. https://druglandscape.com/ci/remifentanil-and-desflurane. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: